share_log

Telescope Innovations Presents Results of First Fiscal Quarter 2024

Telescope Innovations Presents Results of First Fiscal Quarter 2024

望远镜创新公布2024年第一财季业绩
newsfile ·  01/30 08:00

The Company exceeded its quarterly revenue and profit records in Q1, 2024

该公司在2024年第一季度超过了其季度收入和利润记录

Vancouver, British Columbia--(Newsfile Corp. - January 30, 2024) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) ("Telescope" or the "Company"), a developer of advanced technologies and services for the global pharmaceutical and chemical industries, reports financial results for the fiscal quarter ended November 30, 2023. The Company generated revenues of $1.50 M for a net income of $215,000 (Figure 1).

不列颠哥伦比亚省温哥华--(新闻档案公司,2024年1月30日)——望远镜创新公司(CSE:TELI)(OTCQB:TELI)(OTCQB:TELIF)(”望远镜“或者”公司“)是全球制药和化工行业先进技术和服务的开发商,报告了截至2023年11月30日的财季财务业绩。该公司创造了150万美元的收入,净收入为21.5万美元(图1)。


Figure 1. Revenue and net income chart for FY 2022, 2023, and 2024 to date.


图 1。 迄今为止的2022财年、2023年和2024财年的收入和净收入图表。

FINANCIAL HIGHLIGHTS OF THE FISCAL QUARTER ENDED NOVEMBER 30, 2023
All values are represented in CAD.

截至2023年11月30日的财季财务摘要
所有值均在 CAD 中表示。

  • Revenues of $1,504,852: representing 300% growth over Q1, 2023.
  • Expenses of $1,289,852
  • Net income of $215,000
  • 收入为1,504,852美元:比2023年第一季度增长300%。
  • 支出为1,289,852美元
  • 净收入为215,000美元

"Our strong performance this quarter has been driven by the increasing momentum of our flagship product, DirectInject-LCTM," commented Jeffrey Sherman, COO of Telescope. "We have also continued to expand our technology and process development services with strategic partners in the pharmaceutical and chemical manufacturing sectors. Our automation and advanced analytical technology have been making big impacts in these industries by accelerating chemical process development, increasing data quality, and reducing development costs."

“我们本季度的强劲表现是由我们的旗舰产品势头增强所推动的, 直接注射液相色谱法TM,” 望远镜首席运营官杰弗里·谢尔曼评论道。“我们还继续与制药和化学品制造领域的战略合作伙伴一起扩大我们的技术和工艺开发服务。我们的自动化和先进的分析技术通过加速化学工艺开发、提高数据质量和降低开发成本,对这些行业产生了重大影响。”

Readers are encouraged to review the full financial statements and accompanying management discussion and analysis for the quarter ended November 30, 2023, both of which are available under the profile for the Company on SEDAR+ ().

鼓励读者查看截至2023年11月30日的季度的完整财务报表以及随附的管理层讨论和分析,两者均可在SEDAR+()的公司简介下查阅。

About Telescope

关于望远镜

Telescope is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The Company builds and deploys new enabling technologies including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. Our aim is to bring modern chemical technology solutions to meet the most serious challenges in health and sustainability.

Telescope是一家化学技术公司,为制药和化学行业开发可扩展的制造工艺和工具。该公司构建和部署新的支持技术,包括灵活的机器人平台和人工智能软件,以提高实验吞吐量、效率和数据质量。我们的目标是提供现代化学技术解决方案,以应对健康和可持续发展方面最严峻的挑战。

On behalf of the Board,

代表董事会,

Telescope Innovations Corp.

望远镜创新公司

Jeffrey Sherman, Chief Operating Officer
E: jeff@telescopeinn.com

杰弗里·谢尔曼,首席运营官
E: jeff@telescopeinn.com

The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

CSE既未批准也未拒绝本新闻稿的内容。CSE及其市场监管机构(该术语在CSE的政策中定义)均不对本新闻稿的充分性或准确性承担责任。

To view the source version of this press release, please visit

要查看本新闻稿的源版本,请访问

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发